Healius (ASX:HLS) Accounts Payable & Accrued Expense: A$145 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:HLS Healius Ltd ASX:HLS
25 GF Score
Price A$0.46
GF Value A$0.96
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Healius Accounts Payable & Accrued Expense?

Healius ASX:HLS -1.09% 25 Accounts Payable & Accrued Expense is A$145 Mil as of Jun. 2026. GuruFocus rates ASX:HLS with a GF Score™ of 25/100 and a GF Value™ of A$0.96 (Possible Value Trap). The stock has 7 warning signs investors should review.

Healius's quarterly accounts payable & accrued expense increased from Jun. 2025 (A$134 Mil) to Dec. 2025 (A$168 Mil) but then declined from Dec. 2025 (A$168 Mil) to Jun. 2026 (A$145 Mil).

Healius's annual accounts payable & accrued expense declined from Jun. 2024 (A$201 Mil) to Jun. 2025 (A$134 Mil) but then increased from Jun. 2025 (A$134 Mil) to Jun. 2026 (A$145 Mil).

Healius Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Healius's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healius Accounts Payable & Accrued Expense Chart

Healius Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 169.60 218.00 200.90 133.90 145.30

Healius Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 200.90 179.80 133.90 167.60 145.30
ASX:HLS
25GF Score
Healius Ltd ASX:HLS
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healius Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of A$145 Mil mean?
Healius (ASX:HLS) has a Accounts Payable & Accrued Expense of A$145 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Healius and its competitors.
Is Healius' Accounts Payable & Accrued Expense too high?
Healius' current Accounts Payable & Accrued Expense is A$145 Mil. Overall, Healius has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' Accounts Payable & Accrued Expense compare to TMO and DHR?
Healius' Accounts Payable & Accrued Expense of A$145 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Medical Diagnostics & Research company?
A good Accounts Payable & Accrued Expense depends on the Medical Diagnostics & Research industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Healius and its competitors. Healius's current Accounts Payable & Accrued Expense is A$145 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.96, compared to a current price of A$0.46 — trading 52.6% below its estimated fair value. The current Accounts Payable & Accrued Expense is A$145 Mil. Healius' overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Healius (ASX:HLS), the current Accounts Payable & Accrued Expense is A$145 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healius (ASX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, Healius stock appears to be undervalued. The current stock price of A$0.46 is trading 52.6% below its estimated GF Value™ of A$0.96. GuruFocus considers Healius to be Possible Value Trap.

Key valuation signals for ASX:HLS:

  • Accounts Payable & Accrued Expense: A$145 Mil
  • GF Value™: A$0.96 vs. price of A$0.46 (52.6% below fair value)
  • GF Score™: 25/100 with 7 warning signs

No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healius Business Description

Other Exchanges PGZ:Germany
Address 161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
25GF Score

Get the complete analysis for ASX:HLS

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.46
Price
A$0.96
GF Value